Key facts
- This page summarizes Rosemary A. Crane's Form 4 filing for Tarsus Pharmaceuticals, Inc. (TARS).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 14 Jun 2024, 17:40.
Rosemary A. Crane - 13 Jun 2024 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)
- Reporting relationship
- Director
- Issuer ticker
- TARS
- Reported as of
- 13 Jun 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 14 Jun 2024, 17:40:44 UTC
- Prior SEC filing
- 10 Jun 2024
- Next SEC filing
- 17 Jun 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Scott Sieckert, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Rosemary A. Crane filed Form 4 for Tarsus Pharmaceuticals, Inc. (TARS) on 14 Jun 2024.
Change
- Previous filing in this sequence was filed on 10 Jun 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TARS
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +5,000
- Change %
- Price
- $0.000000
- Shares after
- 5,000
- Date
- 13 Jun 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 5,000
- Exercise price
- $33.14
- Footnotes
- F1
TARS
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +3,350
- Change %
- Price
- $0.000000
- Shares after
- 3,350
- Date
- 13 Jun 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,350
- Exercise price
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2024 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.
Footnote F2
Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.
Footnote F3
RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2024 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.
SEC remarks
Exhibit 24- Power of Attorney